scholarly journals In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India

2011 ◽  
Vol 60 (7) ◽  
pp. 961-967 ◽  
Author(s):  
Anuradha Chowdhary ◽  
Harbans Singh Randhawa ◽  
Gandhi Sundar ◽  
Shallu Kathuria ◽  
Anupam Prakash ◽  
...  
2021 ◽  
Vol 12 ◽  
Author(s):  
Najwa Al-Odaini ◽  
Xiu-ying Li ◽  
Bing-kun Li ◽  
Xing-chun Chen ◽  
Chun-yang Huang ◽  
...  

This study analyzed the in vitro drug sensitivity of Cryptococcus spp. from Guangxi, Southern China. One hundred three strains of Cryptococcus were recovered from 86 patients; 14 were HIV positive and 72 were HIV negative. Ninety-two strains were identified as Cryptococcus neoformans var. grubii, while 11 strains were identified as Cryptococcus gattii (5 C. gattii sensu stricto and 6 Cryptococcus deuterogattii). The recovered strains were tested against commonly used antifungal drugs (fluconazole, amphotericin B, 5-fluorocytosine, itraconazole, and voriconazole) and to novel antifungal drugs (posaconazole and isavuconazole) using CLSI M27-A4 method. The results showed that all isolates were susceptible to most antifungal drugs, of which the minimum inhibitory concentration (MIC) ranges were as follows: 0.05–4 μg/ml for fluconazole, 0.25–1 μg/ml for amphotericin B; 0.0625–2 μg/ml for 5-fluorocytosine, 0.0625–0.25 μg/ml for itraconazole, 0.0078–0.25 μg/ml for voriconazole, 0.0313–0.5 μg/ml for posaconazole, 0.0020–0.125 μg/ml for isavuconazole for C. neoformans var. grubii isolates, and 1–16 μg/ml for fluconazole, 0.125–1 μg/ml for 5-fluorocytosine, 0.25–1 μg/ml for amphotericin B, 0.0625–0.25 μg/ml for itraconazole, 0.0156–0.125 μg/ml for voriconazole, 0.0156–0.25 μg/ml for posaconazole, and 0.0078–0.125 μg/ml for isavuconazole for C. gattii isolates. Furthermore, some C. neoformans var. grubii isolates were found to be susceptible-dose dependent to 5-fluorocytosine and itraconazole. In addition, a reduction in the potency of fluconazole against C. gattii is possible. We observed no statistical differences in susceptibility of C. neoformans var. grubii and C. gattii in the tested strains. Continuous observation of antifungal susceptibility of Cryptococcus isolates is recommended to monitor the emergence of resistant strains.


2021 ◽  
Vol 7 (4) ◽  
pp. 347-356
Author(s):  
Hussain Yahaya Ungo-kore ◽  
Joseph Olorunmola Ehinmidu ◽  
Josiah Ademola Onaolapo ◽  
Olayeni Stephen Olonitola ◽  
◽  
...  

1995 ◽  
Vol 23 (3) ◽  
pp. 99-103 ◽  
Author(s):  
Francesco Barchiesi ◽  
Richard J. Hollis ◽  
Shawn A. Messer ◽  
Giorgio Scalise ◽  
Michael G. Rinaldi ◽  
...  

2018 ◽  
Vol 22 (1) ◽  
pp. 30-36 ◽  
Author(s):  
Laura Bedin Denardi ◽  
Bianca Hoch Dalla-Lana ◽  
Francielli Pantella Kunz de Jesus ◽  
Cecília Bittencourt Severo ◽  
Janio Morais Santurio ◽  
...  

2020 ◽  
Vol 64 (4) ◽  
Author(s):  
Fatima Zohra Delma ◽  
Abdullah M. S. Al-Hatmi ◽  
Jochem B. Buil ◽  
Hein van der Lee ◽  
Marlou Tehupeiory-Kooreman ◽  
...  

ABSTRACT We compared MIC test strip (MTS) and Sensititre YeastOne (SYO) methods with EUCAST and CLSI methods for amphotericin B, 5-fluocytosine, fluconazole, voriconazole, and isavuconazole against 106 Cryptococcus neoformans isolates. The overall essential agreement between the EUCAST and CLSI methods was >72% and >94% at ±1 and ±2 dilutions, respectively. The essential agreements between SYO and EUCAST/CLSI for amphotericin B, 5-flucytosine, fluconazole, and voriconazole were >89/>93% and between MTS and EUCAST/CLSI were >57/>75%. Very major error rates were low for amphotericin B and fluconazole (<3%) and a bit higher for the other drugs (<8%).


2016 ◽  
Vol 26 (6) ◽  
pp. 555 ◽  
Author(s):  
William Dongmo ◽  
Frederick Kechia ◽  
Roland Tchuenguem ◽  
Claude Nangwat ◽  
Iwewe Yves ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document